Chen et al. (2020) reported that ALKBH5-mediated m6A modification of PVT1 facilitates osteosarcoma tumorigenesis, indicating that ALKBH5 and PVT1 could be potential therapeutic targets for osteosarcoma treatment. In other research, it was discovered that the TME and expressions of crucial immunological checkpoints in hepatocellular carcinoma and lung adenocarcinoma had strong connections with m6A-related long non-coding RNAs (MRlncRNA) profiles (Li L. et al., 2021b; Xu et al., 2021). The gene discussed is PVT1; the disease is hepatocellular carcinoma.